Eledon Pharmaceuticals (ELDN) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eledon Pharmaceuticals (ELDN) has outperformed Veraxa Biotech (VRXA) over the past year, losing 16.8% versus a loss of 88.0%. Eledon Pharmaceuticals is the larger company by market cap ($201.5 million vs $178.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELDN | VRXA |
|---|---|---|
| Share price | $2.48 | $1.26 |
| Market cap | $201.53M | $178.17M |
| 1-day change | +2.48% | +15.60% |
| YTD return | +64.24% | -88.19% |
| 1-year return | -16.78% | -87.97% |
| 5-year return | -55.95% | — |
| EPS (TTM) | $-0.90 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.60 | $27.36 |
| 52-week low | $1.35 | $1.04 |
| Distance from 52-week high | -46.09% | -95.39% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +262.90% | — |
| Average volume | 935.08K | 267.20K |
| Shares outstanding | 81.26M | 141.41M |
| Employees | 33 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELDN has outperformed VRXA by 71.2 percentage points over the past year.
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
ELDN vs VRXA FAQ
Which is bigger, Eledon Pharmaceuticals or Veraxa Biotech?
Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $201.53M compared with $178.17M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, ELDN or VRXA?
ELDN returned -16.78% over the past 12 months, compared with -87.97% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Eledon Pharmaceuticals and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.